Puma Biotechnology (NASDAQ:PBYI) received a $142.00 target price from research analysts at Credit Suisse Group in a note issued to investors on Monday. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. Credit Suisse Group’s target price suggests a potential upside of 43.07% from the company’s previous close.

Several other equities research analysts have also recently weighed in on the company. Royal Bank of Canada decreased their price target on Puma Biotechnology from $108.00 to $92.00 and set a “sector perform” rating for the company in a research note on Friday, November 10th. They noted that the move was a valuation call. Bank of America reissued a “buy” rating and issued a $135.00 price target (up previously from $117.00) on shares of Puma Biotechnology in a research note on Monday, October 9th. Leerink Swann increased their price target on Puma Biotechnology to $140.00 and gave the company an “outperform” rating in a research note on Friday, October 27th. BidaskClub raised Puma Biotechnology from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, October 3rd. Finally, Citigroup increased their price target on Puma Biotechnology from $156.00 to $164.00 and gave the company a “buy” rating in a research note on Friday, November 10th. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and nine have issued a buy rating to the stock. Puma Biotechnology has a consensus rating of “Buy” and an average price target of $130.67.

Puma Biotechnology (NASDAQ PBYI) opened at $99.25 on Monday. Puma Biotechnology has a fifty-two week low of $28.35 and a fifty-two week high of $136.90. The stock has a market capitalization of $3,724.81, a PE ratio of -12.13 and a beta of 0.72.

Puma Biotechnology (NASDAQ:PBYI) last issued its earnings results on Thursday, November 9th. The biopharmaceutical company reported ($2.07) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.50) by $0.43. The firm had revenue of $6.10 million during the quarter, compared to analyst estimates of $3.78 million. During the same period in the previous year, the company earned ($1.11) EPS. equities research analysts predict that Puma Biotechnology will post -8.17 earnings per share for the current year.

In related news, insider Charles R. Eyler sold 1,322 shares of the company’s stock in a transaction dated Friday, December 1st. The stock was sold at an average price of $105.46, for a total transaction of $139,418.12. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 21.10% of the stock is owned by corporate insiders.

Several institutional investors have recently made changes to their positions in the stock. Ameritas Investment Partners Inc. boosted its position in shares of Puma Biotechnology by 5.9% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 2,522 shares of the biopharmaceutical company’s stock valued at $220,000 after purchasing an additional 140 shares in the last quarter. The Manufacturers Life Insurance Company boosted its position in shares of Puma Biotechnology by 2.0% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 22,299 shares of the biopharmaceutical company’s stock valued at $1,950,000 after purchasing an additional 437 shares in the last quarter. California Public Employees Retirement System boosted its position in shares of Puma Biotechnology by 0.7% during the 3rd quarter. California Public Employees Retirement System now owns 108,000 shares of the biopharmaceutical company’s stock valued at $12,933,000 after purchasing an additional 800 shares in the last quarter. Parametric Portfolio Associates LLC boosted its position in shares of Puma Biotechnology by 13.5% during the 2nd quarter. Parametric Portfolio Associates LLC now owns 7,844 shares of the biopharmaceutical company’s stock valued at $686,000 after purchasing an additional 936 shares in the last quarter. Finally, Rhumbline Advisers boosted its position in shares of Puma Biotechnology by 3.1% during the 3rd quarter. Rhumbline Advisers now owns 34,794 shares of the biopharmaceutical company’s stock valued at $4,167,000 after purchasing an additional 1,061 shares in the last quarter. Institutional investors own 96.00% of the company’s stock.

WARNING: “Puma Biotechnology (PBYI) Given a $142.00 Price Target by Credit Suisse Group Analysts” was first reported by Watch List News and is the sole property of of Watch List News. If you are reading this report on another domain, it was illegally copied and reposted in violation of international trademark and copyright laws. The correct version of this report can be read at https://www.watchlistnews.com/puma-biotechnology-pbyi-given-a-142-00-price-target-by-credit-suisse-group-analysts/1809021.html.

Puma Biotechnology Company Profile

Puma Biotechnology, Inc is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357.

Analyst Recommendations for Puma Biotechnology (NASDAQ:PBYI)

Receive News & Ratings for Puma Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.